I attended National Health IT Week in Washington DC. There were a number of seminars and meetings focused on the growth of health IT in the United States.
Curiously, the FDA seems to be undercutting its own cost savings efforts through its support of a rule that would require unique non-proprietary names with four-character suffixes for biosimilar products. The problem is this proposed naming convention is simply not necessary and could do more harm than good.
Our society’s focus on natural and organic products that promote health has directed scrutiny to chemicals used as preservatives. What is the issue with preservatives?
Any baseball player will tell you how difficult it is to ensure that the ball hits the “sweet spot” on the bat. But their troubles pale in comparison to health system supply chain or value analysis committees.
They say, “Necessity is the mother of invention.” Nowhere is this truer than in the safety net where challenges are magnified by financial pressures, lack of resources and an unknown political landscape. The invention we see there is a far cry from the glamorous world of “think-tank” and “start-up” innovation. Instead, people have to come up with new and better ways of doing things just to get through the day.
The idea that pharmacists should act as care providers has been a part of the healthcare industry discourse for quite some time and has been steadily gaining momentum in recent years.
Be notified about new FDB Blog posts as they are published by submitting the information below. (If you are already an FDB Customer in North America, you are automatically receiving blog updates by email and do not need to sign up.)
VP, Health Policy
Strategic Alliances Director
Strategy and Innovation, CCI
Manager, Consumer Drug Info
Senior VP and Editorial Director
Associate Product Manager
Howell, MD, PhD
VP, Clinical Applications